Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 139Not yet recruiting 51Recruiting 43Completed 40Active not recruiting 8Withdrawn 3Terminated 3Enrolling by invitation 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gallbladder Neoplasms 1Cholangiocarcinoma 1

Interventions

Cisplatin 9Specimen Handling 7Educational Status 7Standard of Care 6Interviews as Topic 6Drug Therapy 6Carboplatin 6Blood Specimen Collection 6Radiotherapy 5Nivolumab 5Chemoradiotherapy 5Surveys and Questionnaires 4Surgical Procedures, Operative 4Paclitaxel 4Oxaliplatin 4Observation 4Lenalidomide 4Fluorouracil 4Fluorodeoxyglucose F18 4Dexamethasone 4pembrolizumab 3lenvatinib 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Gemcitabine 3Exercise 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × anlotinib × Clear all
NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

The First Affiliated Hospital of Zhengzhou University

Phase 2 Enrolling by invitation
50 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡